Ramipril - Moligand™, 10mM in DMSO , Inhibitor of Angiotensin-converting enzyme, CAS No.87333-19-5, Inhibitor of Angiotensin-converting enzyme

CAS: 87333-19-5 Cat. No.: R409196 Summenformel: C₂₃H₃₂N₂O₅ Molekulargewicht: 416.51 EG-Nummer: 642-904-3 PubChem CID: 5362129

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

(2S,​3aS,​6aS)​-1-​[(2S)​-​2-​[[(1S)​-​1-​(ethoxycarbonyl)​-​3-​phenylpropyl]​amino]​-​1-​oxopropyl]​octahydro-cyclopenta[b]​pyrrole-​2-​carboxylic acid

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Übersicht

Information

Ramipril is anangiotensin-converting enzyme (ACE)inhibitor withIC50of 5 nM.
In vitro

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM. Ramipril enhances the activity of ACE-associated CK2 and the phosphorylation of ACE Ser¹²⁷⁰ in cultured endothelial cells, but is unable to activate JNK or stimulate the nuclear accumulation of c-Jun in endothelial cells expressing a S1270A ACE mutant or in ACE-deficient cells. Prolonged Ramipril treatment increases ACE expression in primary cultures of human endothelial cells and in vivo (mouse lung), which can be prevented by pretreatment with the JNK inhibitor SP600125. Ramipril displays little enhanced effect on the rate of in vitro endothelial apoptosis induced by the serum deprivation method.

In vivo

Chronic in vivo administration of Ramipril to rats at a dosage that has similar hypotensive effects in vitro HUVECs significantly reduces the rate of LPS-induced apoptosis compared to the other ACE inhibitors, which contrasts with the apoptosis effect in vitro. Ramipril inhibits systolic blood pressure (SBP) with IC50 of 1.97 mg/kg in spontaneously hypertensive rats (SHR). When in combination with AT1-receptor blockade by candesartan-cilexetil increases SBP reduction synergistically rather than additively. Administration of Ramipril to spontaneously hypertensive rats (SHR) produces significant inhibition of aorta ACE and lung ACE with IC50 ~5 mg/kg, but shows little effect for brain ACE ex vivo. Ramipril prevents beta cell dysfunction in osteoprotegerin treated mice through decreasing islet monocyte/macrophage infiltration, fibrosis and apoptosis involving decreasing RAS, growth factor genes and inflammatory molecules expressions.
Cell Data

cell lines：

Concentrations：~1 μM

Incubation Time：24 hours

Powder Purity:≥99%

Specifications

Synonyme

(2S,​3aS,​6aS)​-1-​[(2S)​-​2-​[[(1S)​-​1-​(ethoxycarbonyl)​-​3-​phenylpropyl]​amino]​-​1-​oxopropyl]​octahydro-cyclopenta[b]​pyrrole-​2-​carboxylic acid

Spezifikationen & Reinheit

Moligand™, 10mM in DMSO

Biochemische und physiologische Mechanismen

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.

Storage

Store at -80°C

Verschickt in

Dry ice packs + Cold packs

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Note

Moligand™

Aktionsart

INHIBITOR

Mechanismus der Wirkung

Inhibitor of Angiotensin-converting enzyme

Produkteigenschaften

• ALogP: 1.4

Namen und Kennungen

• Isomere SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
• WGK Deutschland: 2
• RTECS: GY5879600
• Alternative CAS-Nummer: 87333-19-5
• PubChem CID: 5362129
• NSC-Nummer: 758933
• MeSH-Eintrag: Acovil;Altace;Carasel;Delix;HOE 498;HOE-498;HOE498;Ramace;Ramipril;Triatec;Tritace;Vesdil;Zabien
• Molekulargewicht: 416.51

Zugehörige Ziele (menschlich)

ACE Tclin Angiotensin-converting enzyme (2 Activities)

Discover Target: ACE

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Chemische und physikalische Eigenschaften

• Löslichkeit: Solubility (25°C) In vitro DMSO: 30 mg/mL (197.17 mM); Ethanol: -1 mg/mL
• Spezifische Drehung [α]: 40° (C=1,0.1 NHCl in EtOH)
• Schmelzpunkt (°C): 109 °C

Referenzen

1. Kai Liu, Xing Zhao, Xue Qi, Dong-Liang Hou, Hao-Bin Li, Yu-Hao Gu, Qing-Long Xu.  (2021)  Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.  EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,      [PMID:33784603] [10.1016/j.ejmech.2021.113388]